Literature DB >> 17008888

Detection of a new JAK2 D620E mutation in addition to V617F in a patient with polycythemia vera.

F Grünebach, U Bross-Bach, L Kanz, P Brossart.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 17008888     DOI： 10.1038/sj.leu.2404419

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  10 in total

1.  High resolution melting analysis for JAK2 Exon 14 and Exon 12 mutations: a diagnostic tool for myeloproliferative neoplasms.

Authors:  Inmaculada Rapado; Silvia Grande; Enriqueta Albizua; Rosa Ayala; José-Angel Hernández; Miguel Gallardo; Florinda Gilsanz; Joaquin Martinez-Lopez
Journal:  J Mol Diagn       Date:  2009-03       Impact factor: 5.568

2.  Mechanistic insights into activation and SOCS3-mediated inhibition of myeloproliferative neoplasm-associated JAK2 mutants from biochemical and structural analyses.

Authors:  Leila N Varghese; Daniela Ungureanu; Nicholas P D Liau; Samuel N Young; Artem Laktyushin; Henrik Hammaren; Isabelle S Lucet; Nicos A Nicola; Olli Silvennoinen; Jeffrey J Babon; James M Murphy
Journal:  Biochem J       Date:  2014-03-01       Impact factor: 3.857

Review 3.  A structure-function perspective of Jak2 mutations and implications for alternate drug design strategies: the road not taken.

Authors:  K Gnanasambandan; P P Sayeski
Journal:  Curr Med Chem       Date:  2011       Impact factor: 4.530

Review 4.  The molecular regulation of Janus kinase (JAK) activation.

Authors:  Jeffrey J Babon; Isabelle S Lucet; James M Murphy; Nicos A Nicola; Leila N Varghese
Journal:  Biochem J       Date:  2014-08-15       Impact factor: 3.857

5.  Comparison of mutated ABL1 and JAK2 as oncogenes and drug targets in myeloproliferative disorders.

Authors:  C Walz; N C P Cross; R A Van Etten; A Reiter
Journal:  Leukemia       Date:  2008-06-05       Impact factor: 11.528

6.  Z3, a novel Jak2 tyrosine kinase small-molecule inhibitor that suppresses Jak2-mediated pathologic cell growth.

Authors:  Jacqueline Sayyah; Andrew Magis; David A Ostrov; Robert W Allan; Raul C Braylan; Peter P Sayeski
Journal:  Mol Cancer Ther       Date:  2008-08       Impact factor: 6.261

Review 7.  Perspectives for the use of structural information and chemical genetics to develop inhibitors of Janus kinases.

Authors:  Claude Haan; Iris Behrmann; Serge Haan
Journal:  J Cell Mol Med       Date:  2010-01-28       Impact factor: 5.310

8.  Myelodysplastic Syndrome/Acute Myeloid Leukemia Arising in Idiopathic Erythrocytosis.

Authors:  Stephen E Langabeer; Eibhlin Conneally; Catherine M Flynn
Journal:  Case Rep Hematol       Date:  2018-02-22

9.  Development of a high resolution melting analysis assay for rapid identification of JAK2 V617F missense mutation and its validation.

Authors:  Alireza Moradabadi; Alireza Farsinejad; Behzad Khansarinejad; Ahamd Fatemi
Journal:  Exp Hematol Oncol       Date:  2019-04-30

Review 10.  Molecular drug targets in myeloproliferative neoplasms: mutant ABL1, JAK2, MPL, KIT, PDGFRA, PDGFRB and FGFR1.

Authors:  Ayalew Tefferi
Journal:  J Cell Mol Med       Date:  2008-10-23       Impact factor: 5.310
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.